학술논문

Respiratory syncytial virus activates epidermal growth factor receptor to suppress interferon regulatory factor 1-dependent interferon-lambda and antiviral defense in airway epithelium
Document Type
article
Source
Mucosal Immunology. 11(3)
Subject
Medical Microbiology
Biomedical and Clinical Sciences
Clinical Sciences
Lung
Infectious Diseases
Pneumonia
Pneumonia & Influenza
2.1 Biological and endogenous factors
Aetiology
Respiratory
Infection
Good Health and Well Being
Antigens
Viral
Cell Line
Cytokines
Down-Regulation
ErbB Receptors
Humans
Immunity
Interferon Regulatory Factor-1
Respiratory Mucosa
Respiratory Syncytial Virus Infections
Respiratory Syncytial Viruses
Signal Transduction
Biological Sciences
Medical and Health Sciences
Immunology
Language
Abstract
Respiratory syncytial virus (RSV) persists as a significant human pathogen that continues to contribute to morbidity and mortality. In children, RSV is the leading cause of lower respiratory tract infections, and in adults RSV causes pneumonia and contributes to exacerbations of chronic lung diseases. RSV induces airway epithelial inflammation by activation of the epidermal growth factor receptor (EGFR), a tyrosine kinase receptor. Recently, EGFR inhibition was shown to decrease RSV infection, but the mechanism(s) for this effect are not known. Interferon (IFN) signaling is critical for innate antiviral responses, and recent experiments have implicated IFN-λ (lambda), a type III IFN, as the most significant IFN for mucosal antiviral immune responses to RSV infection. However, a role for RSV-induced EGFR activation to suppress airway epithelial antiviral immunity has not been explored. Here, we show that RSV-induced EGFR activation suppresses IFN regulatory factor (IRF) 1-induced IFN-λ production and increased viral infection, and we implicate RSV F protein to mediate this effect. EGFR inhibition, during viral infection, augmented IRF1, IFN-λ, and decreased RSV titers. These results suggest a mechanism for EGFR inhibition to suppress RSV by activation of endogenous epithelial antiviral defenses, which may be a potential target for novel therapeutics.